RATIONALE: Measuring levels of calgranulin A and calgranulin B in the blood of patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to breast cancer. PURPOSE: This laboratory study is measuring calgranulin A and calgranulin B levels in the blood of patients with newly diagnosed stage I, stage II, or stage III breast cancer.
OBJECTIVES: * Determine circulating levels of calgranulin A and calgranulin B in patients with estrogen receptor negative or estrogen receptor positive, newly diagnosed, primary stage I-III adenocarcinoma of the breast. OUTLINE: This is a pilot study. Patients undergo a blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B. Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression. PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Study Type
OBSERVATIONAL
Enrollment
60
Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Correlation between circulating levels of calgranulin A and calgranulin B and the presence of estrogen receptor negative breast cancer
Time frame: upon diagnosis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.